Paola Brandi

Von Hippel-Lindau Protein Is Required for Optimal Alveolar Macrophage Terminal Differentiation, Self-Renewal, and Function

M. Guilliams, D. Sancho, M. Enamorado, 2018, Cell reports.

Lung CD103+ dendritic cells restrain allergic airway inflammation through IL-12 production.

D. Sancho, Sarai Martínez-Cano, L. Conejero, 2017, JCI insight.

Bacterial Mucosal Immunotherapy with MV130 Prevents Recurrent Wheezing in Children: A Randomized, Double-Blind, Placebo-controlled Clinical Trial

D. Sancho, C. Fernández-Pérez, A. Mazon, 2021, American journal of respiratory and critical care medicine.

Targeting SHIP-1 in Myeloid Cells Enhances Trained Immunity and Boosts Response to Infection

J. Chisholm, W. Kerr, C. del Fresno, 2018, Cell reports.

DNGR-1 limits Flt3L-mediated antitumor immunity by restraining tumor-infiltrating type I conventional dendritic cells

S. Zelenay, I. Melero, C. del Fresno, 2021, Journal for ImmunoTherapy of Cancer.

Human dendritic cells activated with MV130 induce Th1, Th17 and IL‐10 responses via RIPK2 and MyD88 signalling pathways

S. Sánchez-Ramón, B. Perez-Villamil, D. Sancho, 2017, European journal of immunology.

Trained immunity induction by the inactivated mucosal vaccine MV130 protects against experimental viral respiratory infections

A. Dopazo, C. del Fresno, D. Sancho, 2022, Cell reports.

The Bacterial Mucosal Immunotherapy MV130 Protects Against SARS-CoV-2 Infection and Improves COVID-19 Vaccines Immunogenicity

Natalia Vicente, C. Suay-Corredera, M. Pricolo, 2021, Frontiers in Immunology.